Ultragenyx Pharmaceutical (RARE) Debt/Equity Ratio: History & Chart

Ultragenyx Pharmaceutical Inc.(RARE)

Biotechnology · Novato, CA

$14.49-0.01 (-0.09%)

Delayed quote: Oct 6, 2026, 2:05 PM EDT

About Ultragenyx Pharmaceutical Inc.

Ultragenyx Pharmaceutical Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing innovative treatments for rare and ultra-rare genetic conditions. Its operations span North America, Europe, and other international markets. The company's portfolio of marketed biologic products addresses several serious diseases. This includes Crysvita (burosumab), an antibody that targets fibroblast growth factor 23, used to treat X-linked hypophosphatemia and tumor-induced osteomalacia. Mepsevii offers enzyme replacement therapy for both pediatric and adult patients suffering from Mucopolysaccharidosis VII. Dojolvi is available for individuals with long-chain fatty acid oxidation disorders, while Evkeeza (evinacumab) provides a treatment option for homozygous familial hypercholesterolemia. Ultragenyx also boasts a robust pipeline of investigational therapies. Notable candidates include DTX401, an adeno-associated virus 8 (AAV8) gene therapy for glycogen storage disease type Ia, and DTX301, another AAV8 gene therapy aimed at ornithine transcarbamylase deficiency. Other promising developments feature UX143, a human monoclonal antibody for osteogenesis imperfecta; GTX-102, an antisense oligonucleotide designed for Angelman syndrome; UX701, targeting Wilson disease; and UX053, in development for glycogen storage disease type III. To advance its research and development efforts, Ultragenyx Pharmaceutical Inc. maintains strategic collaboration and licensing agreements with numerous partners, such as Kyowa Kirin Co., Ltd., Saint Louis University, REGENXBIO Inc., Bayer Healthcare LLC, GeneTx, Mereo, University of Pennsylvania, Arcturus Therapeutics Holdings Inc., Solid Biosciences Inc., and Daiichi Sankyo Co., Ltd. The company was founded in 2010 and operates from its headquarters in Novato, California.

Novato, CA

1,371 employees

www.ultragenyx.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Emil D. Kakkis

View full financials

RARE Debt to Equity Ratio Metrics

DEBT TO EQUITY RATIO

-4.13

DEBT TO EQUITY RATIO AVG TTM

14.34

DEBT TO EQUITY RATIO AVG 3Y

0.19

DEBT TO EQUITY RATIO AVG 5Y

0.13

DEBT TO EQUITY RATIO AVG 10Y

0.05

DEBT TO EQUITY RATIO AVG 15Y

N/A

DEBT TO EQUITY RATIO AVG 20Y

N/A

CURRENT VS TTM AVG

-128.81%

CURRENT VS 3Y AVG

-2310.50%

CURRENT VS 5Y AVG

-3350.58%

CURRENT VS 10Y AVG

-8062.07%

CURRENT VS 15Y AVG

N/A

CURRENT VS 20Y AVG

N/A

SECTOR MEDIAN · HEALTHCARE

0.11

median of 765 covered companies

CURRENT VS SECTOR MEDIAN

-3855.08%

vs the sector median at left

NAME	MARKET CAP	DEBT TO EQUITY RATIO	TTM	3Y	5Y
Ultragenyx Pharmaceutical Inc. (RARE)	$1.43B	-4.13	14.34	0.19	0.13
Maze Therapeutics, Inc. (MAZE)vs ›	$1.43B	0.13	0.11	1.37	1.37
AnaptysBio, Inc. (ANAB)vs ›	$1.42B	25.47	2.79	1.47	0.99
Certara, Inc. (CERT)vs ›	$1.44B	0.30	0.15	0.22	0.26
Healthcare Services Group, Inc. (HCSG)vs ›	$1.45B	0.03	0.04	0.07	0.06
The Pennant Group, Inc. (PNTG)vs ›	$1.41B	1.38	1.15	1.84	2.31
Kailera Therapeutics, Inc. (KLRA)vs ›	$1.41B	0.01	N/A	N/A	N/A
Braveheart Bio, Inc. (BRVE)vs ›	$1.44B	N/A	N/A	N/A	N/A
Rapport Therapeutics, Inc. Common Stock (RAPP)vs ›	$1.46B	0.02	0.01	0.18	0.18
Taysha Gene Therapies, Inc. (TSHA)vs ›	$1.40B	0.14	0.47	16.23	10.93

NAME

MARKET CAP

DEBT TO EQUITY RATIO

TTM

Ultragenyx Pharmaceutical Inc. (RARE)

$1.43B

-4.13

14.34

0.19

0.13

Maze Therapeutics, Inc. (MAZE)vs ›

$1.43B

0.13

0.11

1.37

AnaptysBio, Inc. (ANAB)vs ›

$1.42B

25.47

2.79

1.47

0.99

Certara, Inc. (CERT)vs ›

$1.44B

0.30

0.15

0.22

0.26

Healthcare Services Group, Inc. (HCSG)vs ›

$1.45B

0.03

0.04

0.07

0.06

The Pennant Group, Inc. (PNTG)vs ›

$1.41B

1.38

1.15

1.84

2.31

Kailera Therapeutics, Inc. (KLRA)vs ›

$1.41B

0.01

N/A

Braveheart Bio, Inc. (BRVE)vs ›

$1.44B

N/A

Rapport Therapeutics, Inc. Common Stock (RAPP)vs ›

$1.46B

0.02

0.01

0.18

Taysha Gene Therapies, Inc. (TSHA)vs ›

$1.40B

0.14

0.47

16.23

10.93

Debt to Equity Ratio FAQ

What is the debt to equity ratio for Ultragenyx Pharmaceutical Inc. (RARE)?

The debt to equity ratio for RARE stock is -4.13.

Is Ultragenyx Pharmaceutical Inc.'s debt to equity ratio high or low?

The debt to equity ratio of -4.13 is 3351% below its 5-year average of 0.13, near the low end of its 5-year range (-15.95–96.60).

What is the TTM average debt to equity ratio for Ultragenyx Pharmaceutical Inc. (RARE)?

The TTM average debt to equity ratio for RARE stock is 14.34.

What is the 3Y average debt to equity ratio for Ultragenyx Pharmaceutical Inc. (RARE)?

The 3Y average debt to equity ratio for RARE stock is 0.19.

What is the 5Y average debt to equity ratio for Ultragenyx Pharmaceutical Inc. (RARE)?

The 5Y average debt to equity ratio for RARE stock is 0.13.

What is the 10Y average debt to equity ratio for Ultragenyx Pharmaceutical Inc. (RARE)?

The 10Y average debt to equity ratio for RARE stock is 0.05.

DATE	DEBT TO EQUITY RATIO
2026-06-30	-4.13
2026-03-31	-5.08
2025-12-31	-15.95
2025-09-30	96.60
2025-06-30	0.24
2025-03-31	0.27
2024-12-31	0.16
2024-09-30	0.10
2024-06-30	0.09
2024-03-31	0.29
2023-12-31	0.16
2023-09-30	1.47
2023-06-30	0.20
2023-03-31	0.13
2022-12-31	0.09
2022-09-30	0.07
2022-06-30	0.06
2022-03-31	0.05
2021-12-31	0.05
2021-09-30	0.05
2021-06-30	0.05
2021-03-31	0.04
2020-12-31	0.04
2020-09-30	0.07
2020-06-30	0.06
2020-03-31	0.07
2019-12-31	0.06
2019-09-30	0.05
2019-06-30	0.05
2019-03-31	0.03
2018-12-31	0.00
2018-09-30	0.00
2018-06-30	0.00
2018-03-31	0.00
2017-12-31	0.00
2017-09-30	0.00
2017-06-30	0.00
2017-03-31	0.00
2016-12-31	0.00
2016-09-30	0.00
2016-06-30	0.00
2016-03-31	0.00
2015-12-31	0.00
2015-09-30	0.00
2015-06-30	0.00
2015-03-31	0.00
2014-12-31	0.00
2014-09-30	0.00
2014-06-30	0.00
2014-03-31	0.00
2013-12-31	0.00
2013-09-30	0.00
2013-06-30	0.00
2013-03-31	0.00
2012-12-31	0.00

DATE

DEBT TO EQUITY RATIO

2026-06-30

-4.13

2026-03-31

-5.08

2025-12-31

-15.95

2025-09-30

96.60

2025-06-30

0.24

2025-03-31

0.27

2024-12-31

0.16

2024-09-30

0.10

2024-06-30

0.09

2024-03-31

0.29

2023-12-31

0.16

2023-09-30

1.47

2023-06-30

0.20

2023-03-31

0.13

2022-12-31

0.09

2022-09-30

0.07

2022-06-30

0.06

2022-03-31

0.05

2021-12-31

0.05

2021-09-30

0.05

2021-06-30

0.05

2021-03-31

0.04

2020-12-31

0.04

2020-09-30

0.07

2020-06-30

0.06

2020-03-31

0.07

2019-12-31

0.06

2019-09-30

0.05

2019-06-30

0.05

2019-03-31

0.03

2018-12-31

0.00

2018-09-30

0.00

2018-06-30

0.00

2018-03-31

0.00

2017-12-31

0.00

2017-09-30

0.00

2017-06-30

0.00

2017-03-31

0.00

2016-12-31

0.00

2016-09-30

0.00

2016-06-30

0.00

2016-03-31

0.00

2015-12-31

0.00

2015-09-30

0.00

2015-06-30

0.00

2015-03-31

0.00

2014-12-31

0.00

2014-09-30

0.00

2014-06-30

0.00

2014-03-31

0.00

2013-12-31

0.00

2013-09-30

0.00

2013-06-30

0.00

2013-03-31

0.00

2012-12-31

0.00

Debt to Equity Ratio: -4.13

RARE Debt to Equity Ratio

RARE Average Debt to Equity Ratio Chart

RARE Current vs Average Debt to Equity Ratio Chart

RARE Debt to Equity Ratio Metrics

RARE Competitors' Debt to Equity Ratio

Financial Health

Debt to Equity Ratio Formula & Definition

Debt to Equity Ratio FAQ

RARE Debt to Equity Ratio History

Related Metrics